8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                        MAY 4, 2011 (SEPTEMBER 29, 2010)
                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

                         COMPETITIVE TECHNOLOGIES, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                    DELAWARE
                                    --------
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)

                           1-8696          36-2664428
                           ------          ----------
         (COMMISSION FILE NUMBER)     (IRS EMPLOYER IDENTIFICATION NO.)


             1375 KINGS HIGHWAY EAST, FAIRFIELD, CONNECTICUT 06824
             -----------------------------------------------------
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)

                                 (203) 368-6044
                                 --------------
              REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:

                777 COMMERCE DRIVE, FAIRFIELD, CONNECTICUT 06825
                ------------------------------------------------
         (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange  Act  (17  CFR  240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange  Act  (17  CFR  240.13e-4(c))

                                   CTTC8K5401

ITEM 1.01.  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

Restore Medical Therapies, Inc.

On April 20, 2011, Competitive Technologies, Inc. (the "Company") entered into a
Sales agreement with Restore Medical Therapies, Inc.  ("RMT").  RMT plans to
establish pain treatment centers using the Company's Calmare  Pain Therapy
Treatment medical devices in several locations in the US, beginning with at
least one in Wyoming, and is also considering several international locations.

Under the agreement, RMT will have exclusivity in several listed regions
provided that RMT opens its centers and purchases a minimum number of Calmare
devices pursuant to an established timeline.  Purchase of the two initial
Calmare  devices for use in Wyoming must be completed by May 31, 2011.  Purchase
of four devices for use in Colorado must be completed by August 31, 2011.  The
agreement

Exclusivity in these regions, and in certain other regions of interest listed in
the agreement, is contingent upon actually opening treatment centers and
purchasing the minimum number of units.  If the Company receives a purchase
offer in one of the listed regions before RMT opens a treatment center in that
region, RMT will have a right of first refusal.  Exclusivity also does not
prevent the Company from selling to hospitals, medical centers, hospice centers,
private hospice centers, any Department of Veterans Affairs medical facilities,
Department of Defense medical facilities and Native American government medical
centers in any region.

Spero Pain Relief Therapy, Inc.

On September 29, 2010, the Company entered into a Sales agreement with Spero
Pain Relief Therapy, Inc. ("Spero"), which was amended February 4, 2011.  Under
the amended agreement, Spero will establish eighteen clinics in the Western
United States using the Company's Calmare  Pain Therapy Treatment medical
devices in exchange for regional exclusivity.

Exclusivity in these regions, and in certain other regions of interest listed in
the Agreement, is contingent upon actually opening treatment centers and
purchasing the minimum number of units.  Exclusivity does not prevent the
Company from selling to hospitals, medical centers, hospice centers, private
hospice centers, any Department of Veterans Affairs medical facilities,
Department of Defense medical facilities and Native American government medical
centers in any region.

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.

The following exhibits are filed herewith:

No.     Description
---     -----------

10.1    Sales Agreement Between Competitive Technologies, Inc. and Restore
        Medical Therapies, LLC dated April 20, 2011. Pursuant to Rule 24b-2 of
        the Exchange Act, confidential information has been omitted and marked
        as "[Confidential Information Omitted]", and has been filed separately
        with the Securities and Exchange Commission pursuant to a Confidential
        Treatment Application filed with the Commission.

10.2    Sales Agreement Between Competitive Technologies, Inc. and Spero Pain
        Relief Therapy, Inc. dated September 29, 2010. Pursuant to Rule 24b-2 of
        the Exchange Act, confidential information has been omitted and marked
        as "[Confidential Information Omitted]", and has been filed separately
        with the Securities and Exchange Commission pursuant to a Confidential
        Treatment Application filed with the Commission.

10.3    Amendment to the Sales Agreement Between Competitive Technologies, Inc.
        and Spero Pain Relief Therapy, Inc. dated February 4, 2011. Pursuant to
        Rule 24b-2 of the Exchange Act, confidential information has been
        omitted and marked as "[Confidential Information Omitted]", and has been
        filed

                                   CTTC8K5402

        separately with the Securities and Exchange Commission pursuant to a
        Confidential Treatment Application filed with the Commission.

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                         COMPETITIVE TECHNOLOGIES, INC.
                                  (Registrant)

Dated: May 4, 2011                    By: /s/ Johnnie D. Johnson
                                      --------------------------
                                      Johnnie D. Johnson
                                      Chief Executive Officer



































                                   CTTC8K5402

EX-10.1

Exhibit 10.1

April 20, 2011

Robert A. Schlidt, MD
Restore Medical Therapies, LLC
4940 Dexter
Casper, Wyoming 82609


RE:  Sales Agreement Between Competitive Technologies, Inc. and Restore Medical
Therapies, LLC

Dear Dr. Schlidt,

Based on your discussions with our sales representatives, Competitive
Technologies is pleased to agree to the following:

1.     Restore Medical Therapies ("RMT") will establish at least one treatment
center utilizing Competitive Technologies, Inc.'s ("CTTC") Calmare(R) Pain
Therapy Treatment medical device, model MC-5A, located in Wyoming.

CTTC will grant RMT exclusive territory in the State of Wyoming for three (3)
years from the date of this agreement in exchange for the purchase of a minimum
of two (2) Calmare(R) devices.  This exclusivity does not preclude CTTC's sales
of the Calmare(R) MC-5A device to hospitals, medical centers, hospice centers,
private hospice centers, any Department of Veterans Affairs medical facilities,
Department of Defense medical facilities and Native American government medical
centers

The first Calmare(R) device was shipped to RMT in anticipation of this
agreement, with payment expected upon signing.  The second device for Wyoming
will be shipped to RMT by the end of May 2011, with payment due no later than
May 31, 2011.  Pricing for devices, supplies and training are outlined on
Schedule A.  The pricing listed is guaranteed for all purchases through the end
of January 2013.

2.     RMT plans to establish additional treatment centers, according to the
time frame shown on Schedule B, in the following locations: Colorado Front Range
(Denver, Fort Collins, Colorado Springs), [Confidential Information Omitted].
Schedule B also indicates existing restrictions, if they exist, in these
locations.

International locations under consideration by RMT for clinics - [Confidential
Information Omitted] - may be addressed under separate agreements with CTTC, as
the requirements for international sales are not identical to domestic sales.

*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5404

3.     RMT will be granted exclusive territory within the Colorado Front Range
area for three (3) years from the date of this agreement, in exchange for the
purchase of a minimum of four (4) Calmare(R) devices, with these purchases to be
completed by August 31, 2011.  This exclusivity does not preclude CTTC's sales
of the Calmare(R) MC-5A device to hospitals, medical centers, hospice centers,
private hospice centers, any Department of Veterans Affairs medical facilities,
Department of Defense medical facilities and Native American government medical
centers.

4.     Continued exclusivity in any location is predicated on RMT's purchase of
the minimum number of devices indicated on Schedule B.  Should the purchase plan
be delayed or curtailed, exclusivity in more localized areas will be based on
clinic locations, population density in vicinity of clinics, and number of
devices purchased.  CTTC's current rule of thumb is that a population of 100,000
can support a minimum of two (2) Calmare(R) devices.

5.     Exclusivity for the additional metropolitan areas listed in paragraph 3 -
[Confidential Information Omitted] - will be addressed as RMT's plan for each
region is developed.  Before those plans develop, should CTTC receive sales
opportunities from other purchasers, CTTC will offer RMT the right of first
refusal in those areas.  Upon indication that another entity is interested in
one of those locations, CTTC will advise RMT of such interest.  RMT will then
have five (5) business days to agree to move into that location and must open a
treatment center in the desired location within 45 days of so agreeing.

Similarly, should another entity indicate interest in a territory in one of the
RMT locations, but not in close proximity to an existing or planned RMT
treatment center, RMT will be offered the right of first refusal for an
additional treatment facility in that location.  RMT will then have five (5)
business days to agree to move into that location and must open a treatment
center in the desired location within 45 days of so agreeing.

6.     The Calmare warranty is attached as Schedule C.  CTTC provides complete
device replacement at no cost in year one.  In years two through five, CTTC
provides replacement parts at no cost, shipping and labor costs would be borne
by RMT.

7.     This agreement is transferable and binding upon any new owners in the
event of the change of control or ownership of either CTTC or RMT.  If at any
time RMT stops using the device for an extended period, any exclusivity offered
based this agreement is void.

We at Competitive Technologies look forward to a long and mutually beneficial
business relationship with Restore Medical Therapies over the coming months and
years.

Sincerely,


___________________________     ____________________________
Johnnie D. Johnson              Robert A. Schlidt, MD
Chief Executive Officer         Restore Medical Therapies, LLC
Competitive Technologies, Inc.  Date

*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5405


          SCHEDULE A - RESTORE MEDICAL THERAPIES/CTTC SALES AGREEMENT

                            PRICING FOR PURCHASE OF
               CALMARE(R) PAIN THERAPY TREATMENT MEDICAL DEVICE,
                       DISPOSABLE SUPPLIES, AND TRAINING


CALMARE(R)PAIN THERAPY TREATMENT MEDICAL DEVICE.  The price for each Calmare(R)
------------------------------------------------
Pain Therapy Treatment medical device, model MC-5A, is as follows:
     $[Confidential Information Omitted]

GEOMC Co., Ltd. of Korea in Seoul, South Korea is the manufacturer.  Devices
will be shipped - either from CTTC's U.S. warehouse or direct from manufacturer
- upon receipt of financing documentation or notice of successful wire transfer
of funds.

DISPOSABLE SUPPLIES. Each device purchased, leased or rented includes a package
--------------------
of five (5) cables and four (4) packages of electrodes (30 latex-free electrode
pads per package).  Pricing for additional packages of these supplies is shown
below:

-    5-Cable Package:                                    $[Confidential
                                                           Information Omitted]
-    30-Electrode Package:
     1 package (30 electrode pads)                       $[Confidential
                                                           Information Omitted]
     40 packages (30 electrodes per package) per box     $[Confidential
                                                           Information Omitted]

TRAINING. A three-day training session for physicians and nurses or technicians
---------
will be provided with the delivery of the first device to each location.
Additional training at purchaser's desired facility:  $[Confidential Information
Omitted]/Day plus travel and expenses



*Confidential information on this page has been omitted Pursuant to Rule 24b-2*







                                   CTTC8K5406

          SCHEDULE B - RESTORE MEDICAL THERAPIES/CTTC SALES AGREEMENT

                 TREATMENT CENTER LOCATIONS AND PURCHASING PLAN
Initial plan is for minimum of 4 devices per location:

                                          Minimum
                                          Purchase
                                          within 1 year
                        Timing of         of Treatment
                        Treatment Center  Center
Location                Opening           Opening*       Location Comments
----------------------  ----------------  -------------  -----------------
Wyoming                 April 2011                    2
----------------------  ----------------  -------------  -----------------
Colorado Front Range
[Denver, Fort Collins,
Colorado Springs]       June 2011                     4
----------------------  ----------------  -------------  -----------------

                       [Confidential Information Omitted]

NOTE: CTTC HAS AN ONGOING RELATIONSHIP WITH U.S. ONCOLOGY FOR THE TREATMENT OF
THEIR ONCOLOGY PATIENTS AND THEIR FACILITIES MAY BE LOCATED FROM TIME TO TIME IN
THE ABOVE AREAS.

*This is a minimum number of devices anticipated to be needed for initial start
up of a single clinic/treatment center in a metropolitan area.  CTTC's rule of
thumb is that a population of 100,000 can support a minimum of two (2)
Calmare(R) devices, thus in larger metropolitan areas it is anticipated that
additional devices and/or treatment center locations would be added in future
years.
















*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5407

EX-10.2

Exhibit 10.2

September 29, 2010


Spero Pain Relief Therapy, LLC
348 E. 600 S.
St. George, UT 84770

RE: Sales Agreement Between Competitive Technologies, Inc. and Spero Pain Relief
Therapy, LLC

Dear Mr. Miller and Dr. Chalmers,

Based on our discussions, we are pleased to agree to the following:

1.     Spero Pain Relief Therapy, LLC ("Spero"), and its affiliates will, in
selected areas, establish 14 treatment centers utilizing Competitive
Technologies, Inc.'s ("CTTC") Calmare  Pain Therapy Treatment medical device,
model MC-5A.

2.     Spero will be granted exclusive territory within the defined zip codes
listed on schedule A for each selected region listed on Schedule B for five (5)
years from the date of this agreement.  This continued exclusivity is predicated
on Spero's purchase or lease of the minimum number of devices indicated on
Schedule B.  Schedule C is an initial proposed maximum level of devices for each
region.  That might increase based on demand in each region.  This exclusivity
does not preclude CTTC sales to hospitals and their medical centers for
inpatient treatment, hospice centers, private hospice centers or any Department
of Veterans Affairs or Department of Defense medical facilities or Native
American government medical centers.

3.     Pricing for devices, supplies and training are outlined on Schedule D.
The pricing listed is guaranteed for all purchases through the end of December
2012.

4.     In addition to the above, Spero will purchase two Calmare devices by
October 31, 2010, including the one currently in use at the Office of Dr.
Chalmers in St. George, UT.

5.     The Calmare warranty is attached as Schedule E.  CTTC provides complete
device replacement at no cost in year one.  In years 2-5, CTTC provides
replacement parts at no cost, shipping and labor costs would be borne by Spero.

6.     This agreement is transferable and binding upon any new owners in the
event of the change of control or ownership of either CTTC or Spero.

                                   CTTC8K5408

                      SPERO/CTTC SALES AGREEMENT (PAGE 2)


We at Competitive Technologies look forward to a long and mutually beneficial
business relationship with Spero Pain Relief Therapy over the coming months and
years.

Sincerely,


-------------------------------------  ----------------------------------------
Johnnie D. Johnson                     Signature Spero Pain Relief Therapy, LLC
Chief Executive Officer                Printed Name
Competitive Technologies, Inc.         Date



                                       ----------------------------------------
                                       Signature Spero Pain Relief Therapy, LLC
                                       Printed Name
                                       Date





























                                   CTTC8K5409

                    SCHEDULE A - SPERO/CTTC SALES AGREEMENT
                  SPERO PAIN RELIEF THERAPY DEFINED ZIP CODES

                       [Confidential Information Omitted]











































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                  CTTC8K5410

                    SCHEDULE B - SPERO/CTTC SALES AGREEMENT
          MINIMUM DEVICE PLAN FOR SELECTED OFFICE LOCATIONS, BY REGION

                       [Confidential Information Omitted]









































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                  CTTC8K5411


                    SCHEDULE C - SPERO/CTTC SALES AGREEMENT
          MAXIMUM DEVICE PLAN FOR SELECTED OFFICE LOCATIONS, BY REGION

                       [Confidential Information Omitted]









































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                  CTTC8K54012

                    SCHEDULE D - SPERO/CTTC SALES AGREEMENT

                            PRICING FOR PURCHASE OF
                CALMARE  PAIN THERAPY TREATMENT MEDICAL DEVICE,
                       DISPOSABLE SUPPLIES, AND TRAINING


CALMARE PAIN THERAPY TREATMENT MEDICAL DEVICE. The price for each Calmare Pain
----------------------------------------------
Therapy Treatment medical device, model MC-5A, is $[Confidential Information
Omitted], Ex Works Manufacturer.  GEOMC Co., Ltd. of Korea in Seoul, South Korea
is the manufacturer. Devices will be shipped upon receipt of financing
documentation or notice of successful wire transfer of funds.


DISPOSABLE SUPPLIES. Each device purchased, leased or rented includes a package
--------------------
of five (5) cables and ten (10) packages of electrodes (10 latex-free electrode
pads per package).  Pricing for additional packages of these supplies is shown
below:
-     5-Cable Package: $[Confidential Information Omitted]
-     10-Pad Package:  $[Confidential Information Omitted]

TRAINING. A three-day training session for physicians and nurses or technicians
---------
will be provided with the delivery of each device to each location. Additional
training at purchaser's desired facility:  $[Confidential Information
Omitted]/Day plus travel and expenses


















*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                  CTTC8K5413

EX-10.3

Exhibit 10.3

February 4, 2011


Spero Pain Relief Therapy, LLC
348 E. 600 S.
St. George, UT 84770

RE: Amendment to Sales Agreement Between Competitive Technologies, Inc. and
Spero Pain Relief Therapy, LLC, dated September 30, 2010

Dear Mr. Miller and Dr. Chalmers,

Based on our discussions, we are pleased amend our agreement with you which is
dated September 30, 2010 as follows:

1.     Spero Pain Relief Therapy, LLC ("Spero"), and its affiliates will, in
selected areas, establish 18 treatment centers utilizing Competitive
Technologies, Inc.'s ("CTTC") Calmare  Pain Therapy Treatment medical device,
model MC-5A.  The original agreement was for 14 clinics.  The 4 additional
clinics are in [Confidential Information Omitted].

2.     Schedule A-1 is amended to include the zip codes for [Confidential
Information Omitted] on Amended Schedule B.  Continued exclusivity is predicated
on Spero's purchase or lease of the minimum number of devices indicated on
Schedule B.

3.     The exclusivity conditions, pricing for devices, supplies and training,
as well as warranty provisions of the original agreement remain in place.

4.     This agreement is transferable and binding upon any new owners in the
event of the change of control or ownership of either CTTC or Spero.

We at Competitive Technologies look forward to a long and mutually beneficial
business relationship with Spero Pain Relief Therapy over the coming months and
years.

Sincerely,


-------------------------------------  ----------------------------------------
Johnnie D. Johnson                     Signature Spero Pain Relief Therapy, LLC
Chief Executive Officer                Printed Name
Competitive Technologies, Inc.         Date



                                       ----------------------------------------
                                       Signature Spero Pain Relief Therapy, LLC
                                       Printed Name
                                       Date


*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5414

      SCHEDULE A-1 - SPERO/CTTC SALES AGREEMENT, AMENDED JANUARY 26, 2011
                  SPERO PAIN RELIEF THERAPY DEFINED ZIP CODES

                       [Confidential Information Omitted]











































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5415

       SCHEDULE B-1, SPERO/CTTC SALES AGREEMENT, AMENDED JANUARY 26, 2011
              DEVICE PLAN FOR SELECTED OFFICE LOCATIONS, BY REGION

                       [Confidential Information Omitted]











































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5416

       SCHEDULE B-1, SPERO/CTTC SALES AGREEMENT, AMENDED JANUARY 26, 2011
              DEVICE PLAN FOR SELECTED OFFICE LOCATIONS, BY REGION

                       [Confidential Information Omitted]











































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5417

       SCHEDULE B-1, SPERO/CTTC SALES AGREEMENT, AMENDED JANUARY 26, 2011
              DEVICE PLAN FOR SELECTED OFFICE LOCATIONS, BY REGION

                       [Confidential Information Omitted]











































*Confidential information on this page has been omitted Pursuant to Rule 24b-2*

                                   CTTC8K5418